ONCOCYTE CORP: Change of Directors or Principal Officers, Financial Statements and Exhibits (Form 8-K)
Article 5.02 – Departure of directors or certain managers; Election of directors; Appointment of certain leaders; Compensatory provisions of certain executives.
(the “Company” or “Oncocyte”) has adopted compensation programs for the Company’s Senior Vice President, Finance and Interim Chief Financial Officer
CFO Salary, Relocation and Grant of Time-Based Options
COO salary, relocation and time-based RSU subsidy
RSU Long-Term Incentive Grant to CFO, COO and CSO
Number of Name of Executive Office Restricted Stock Units Senior Vice President, Finance, and Interim Anish John Chief Financial Officer 150,000 Gisela Paulsen Chief Operating Officer 350,000 Douglas Ross Chief Scientific Officer 150,000
The RSUs to be granted to each of the executive officers will be granted pursuant to the plan. One hundred percent of the RSUs will vest on
CEO Bonus Award Modifications
Item 9.01 – Financial statements and supporting documents.
Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
© Edgar Online, source